XML 39 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Note 14 - Acquisition of Klondex Mines Ltd.
9 Months Ended
Sep. 30, 2018
Notes to Financial Statements  
Business Combination Disclosure [Text Block]
Note
14.
Acquisition of Klondex Mines Ltd.
 
On
July 20, 2018,
we acquired all of the issued and outstanding common shares of Klondex Mines Ltd. ("Klondex") for consideration valued at
$2.24
per Klondex share (the "Arrangement"). The acquisition resulted in our
100%
ownership of
three
producing gold mines, along with interests in various gold exploration properties, in northern Nevada. The acquisition is expected to increase our annual gold production, gives us ownership of operating gold mines and identified gold reserves and other mineralized material, and provides access to a large land package with known mineralization. Under the terms of the Arrangement, each holder of Klondex common shares had the option to receive either (i)
$2.47
in cash (the “Cash Alternative”), (ii)
0.6272
of a Hecla share per Klondex share (the “Share Alternative”), or (iii)
US$0.8411
in cash and
0.4136
of a Hecla share per Klondex share (the “Combined Alternative”), subject in the case of the Cash Alternative and the Share Alternative to pro-ration based on a maximum cash consideration of
$153.2
million and a maximum number of Hecla shares issued of
75,276,176.
Klondex shareholders also received shares of a newly formed company which holds the Canadian assets previously owned by Klondex (Havilah Mining Corporation (“Havilah”)). Klondex had
180,499,319
issued and outstanding common shares prior to consummation of the Arrangement. An additional
1,549,626
Klondex common shares were issued immediately prior to consummation of the Arrangement related to conversion of in-the-money Klondex options and certain outstanding restricted share units, resulting in a total of
182,048,945
issued and outstanding Klondex common shares at the time of consummation of the Arrangement. In connection with the Arrangement, we also issued an aggregate of
4,136,000
warrants to purchase
one
share of our common stock (“Hecla Warrants”) to holders of warrants to purchase Klondex common shares. Of the Hecla Warrants,
2,068,000
 have an exercise price of
$8.02
and expire in
April 2032,
and 
2,068,000
 have an exercise price of
$1.57
and expire in
February 2029.
In addition, we settled share-based payment awards held by Klondex directors and employees for cash of
$2.0
million. Consideration for the Arrangement was cash of
$161.7
million,
75,276,176
shares of our common stock valued at
$242.4
million, and issuance of the Hecla Warrants valued at
$10.2
million, for total consideration of
$414.2
million. The cash consideration includes
$7.0
million for our subscription for common shares of Havilah and
$1.5
million for settlement of certain equity compensation instruments.
 
 
The following summarizes the preliminary allocation of purchase price to the fair value of assets acquired and liabilities assumed as of the date of acquisition (in thousands):
 
Consideration:
 
 
 
 
Cash payments
  $
161,704
 
Hecla stock issued (75,276,176 shares at $3.22 per share)
   
242,389
 
Hecla warrants issued
   
10,155
 
Total consideration
  $
414,248
 
         
Fair value of net assets acquired:
 
 
 
 
Assets:
       
Cash
  $
12,874
 
Accounts receivable
   
3,453
 
Inventory - supplies
   
6,564
 
Inventory - finished goods, in-process material and stockpiled ore
   
10,302
 
Other current assets
   
2,583
 
Properties, plants, equipment and mineral interests
   
502,285
 
Non-current investments
   
1,596
 
Non-current restricted cash and investments
   
9,504
 
Total assets
   
549,161
 
Liabilities:
       
Accounts payable and accrued liabilities
   
17,270
 
Accrued payroll and related benefits
   
10,352
 
Accrued taxes
   
421
 
Lease liability
   
2,080
 
Debt
   
35,086
 
Asset retirement obligation
   
19,571
 
Deferred tax liability
   
50,133
 
Total liabilities
   
134,913
 
Net assets
  $
414,248
 
 
We do
not
believe there are any specific elements of the allocation of purchase price above that are subject to change. However, the overall allocation is preliminary and is subject to change.
 
Our results for the
nine
months ended
September 
30,
2018
include sales of products of
$11.5
million and a net loss of
$10.1
million since the acquisition date related to the operations acquired through the Arrangement.
 
The unaudited pro forma financial information below represents the combined results of our operations as if the acquisition had occurred at the beginning of the periods presented. The unaudited pro forma financial information is presented for informational purposes only and is
not
indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the periods presented, nor is it indicative of future operating results.
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
(in thousands, except per share amounts)
 
2018
   
2017
   
2018
   
2017
 
Sales
  $
156,731
    $
182,489
    $
543,741
    $
573,950
 
Net (loss) income
   
(20,735
)
   
(8,877
)
   
4,694
     
2,523
 
(Loss) income applicable to common shareholders
   
(20,873
)
   
(9,015
)
   
4,280
     
(2,937
)
Basic and diluted (loss) income per common share
   
(0.04
)
   
(0.02
)
   
0.01
     
(0.01
)
 
The pro forma financial information includes adjustments to eliminate amounts related to the Canadian assets previously owned by Klondex, which were transferred to Havilah and
not
acquired by us, and costs related to the acquisition.